Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04697719 · ClinicalTrials.gov registry record · Phase 4
Body Weight, Aspirin Dose and Pro-resolving Mediators
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 103
- Enrollment target
NCT04697719 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 103 participants.
The verdict
NCT04697719, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 103 participants
- Enrollment target
Study Summary
This study employs a placebo-controlled randomized cross-over design to investigate the impact of body weight and aspirin dose on levels of specialized pro-resolving lipid mediators in blood and neutrophils.
Interventions
- DRUG Aspirin 325mg
- DRUG Aspirin 81mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2021-11-04 |
| Est. Completion | 2025-01-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04697719
The ClinicalTrials.gov registry entry for NCT04697719 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aspirin 325mg is the first listed.
NCT04697719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04697719 about?
NCT04697719 is a clinical study titled "Body Weight, Aspirin Dose and Pro-resolving Mediators". This study employs a placebo-controlled randomized cross-over design to investigate the impact of body weight and aspirin dose on levels of specialized pro-resolving lipid mediators in blood and neutrophils.
What is the current status of trial NCT04697719?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 103 participants. The study started on 2021-11-04. Estimated completion is 2025-01-29.
What interventions are being tested in trial NCT04697719?
The interventions under investigation include: Aspirin 325mg (DRUG), Aspirin 81mg (DRUG).
Who is sponsoring clinical trial NCT04697719?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.